181 related articles for article (PubMed ID: 35418980)
21. PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma.
Zhang H; Wang Y; Zhao Y; Liu T; Wang Z; Zhang N; Dai Z; Wu W; Cao H; Feng S; Zhang L; Cheng Q; Liu Z
CNS Neurosci Ther; 2022 Nov; 28(11):1748-1766. PubMed ID: 35855654
[TBL] [Abstract][Full Text] [Related]
22. Integrated clustering signature of genomic heterogeneity, stemness and tumor microenvironment predicts glioma prognosis and immunotherapy response.
Wu Y; Mao M; Wang LJ
Aging (Albany NY); 2023 Sep; 15(17):9086-9104. PubMed ID: 37698534
[TBL] [Abstract][Full Text] [Related]
23. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction.
Wang S; He Z; Wang X; Li H; Liu XS
Elife; 2019 Nov; 8():. PubMed ID: 31767055
[TBL] [Abstract][Full Text] [Related]
24. Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas.
Zhou Z; Wei J; Yang Z; Bao Y; Jiang W; Lu B; Wang W; Li L
Sci Rep; 2022 Feb; 12(1):1872. PubMed ID: 35115572
[TBL] [Abstract][Full Text] [Related]
25. Upregulated Immunogenic Cell-Death-Associated Gene Signature Predicts Reduced Responsiveness to Immune-Checkpoint-Blockade Therapy and Poor Prognosis in High-Grade Gliomas.
Tang X; Guo D; Yang X; Chen R; Jiang Q; Zeng Z; Li Y; Li Z
Cells; 2022 Nov; 11(22):. PubMed ID: 36429083
[No Abstract] [Full Text] [Related]
26. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
27. A Calcium-Related Immune Signature in Prognosis Prediction of Patients With Glioma.
Lin C; Chen J; Su Z; Liu P; Liu Z; Zhu C; Xu D; Lin Z; Xu P; Liu G; Liu X
Front Cell Dev Biol; 2021; 9():723103. PubMed ID: 34650975
[No Abstract] [Full Text] [Related]
28. Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma.
Wang M; Zhou Z; Zheng J; Xiao W; Zhu J; Zhang C; Jiang X
Front Oncol; 2021; 11():650153. PubMed ID: 34055619
[TBL] [Abstract][Full Text] [Related]
29. Natural killer cell-related gene signature predicts malignancy of glioma and the survival of patients.
Li C; Liu F; Sun L; Liu Z; Zeng Y
BMC Cancer; 2022 Mar; 22(1):230. PubMed ID: 35236310
[TBL] [Abstract][Full Text] [Related]
30. Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma.
Qi Y; Chen D; Lu Q; Yao Y; Ji C
Dis Markers; 2019; 2019():3917040. PubMed ID: 31885736
[TBL] [Abstract][Full Text] [Related]
31. A B7-CD28 Family-Based Signature Demonstrates Significantly Different Prognosis and Immunological Characteristics in Diffuse Gliomas.
Deng X; Chen K; Ren J; Zeng J; Zhang Q; Li T; Tang Q; Zhu J
Front Mol Biosci; 2022; 9():849723. PubMed ID: 35928223
[TBL] [Abstract][Full Text] [Related]
32. A Novel Risk Signature with Seven Pyroptosis-Related Genes for Prognosis Prediction in Glioma.
Huang Q; Li J; Mo L; Zhao Y
World Neurosurg; 2022 Mar; 159():e285-e302. PubMed ID: 34929369
[TBL] [Abstract][Full Text] [Related]
33. PTPN7 mediates macrophage-polarization and determines immunotherapy in gliomas: A single-cell sequencing analysis.
Ji X; Cheng J; Su J; Wen R; Zhang Q; Liu G; Peng Y; Mao J
Environ Toxicol; 2024 Apr; ():. PubMed ID: 38581214
[TBL] [Abstract][Full Text] [Related]
34. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas.
Luo C; Liu Z; Ye W; Liu F
Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164
[No Abstract] [Full Text] [Related]
35. Identification and validation of a 17-gene signature to improve the survival prediction of gliomas.
Tong S; Xia M; Xu Y; Sun Q; Ye L; Cai J; Ye Z; Tian D
Front Immunol; 2022; 13():1000396. PubMed ID: 36248799
[TBL] [Abstract][Full Text] [Related]
36. A Novel Signature Constructed by RNA-Binding Protein Coding Genes to Improve Overall Survival Prediction of Glioma Patients.
Tu Z; Shu L; Li J; Wu L; Tao C; Ye M; Zhu X; Huang K
Front Cell Dev Biol; 2020; 8():588368. PubMed ID: 33634092
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
38. Novel Immune Infiltrating Cell Signature Based on Cell Pair Algorithm Is a Prognostic Marker in Cancer.
Zhang H; Wang Z; Dai Z; Wu W; Cao H; Li S; Zhang N; Cheng Q
Front Immunol; 2021; 12():694490. PubMed ID: 34594324
[TBL] [Abstract][Full Text] [Related]
39. Bioinformatic Analyses Identify a Prognostic Autophagy-Related Long Non-coding RNA Signature Associated With Immune Microenvironment in Diffuse Gliomas.
Xu S; Tang L; Liu Z; Yang K; Cheng Q
Front Cell Dev Biol; 2021; 9():694633. PubMed ID: 34211979
[TBL] [Abstract][Full Text] [Related]
40. Classifying lower grade glioma cases according to whole genome gene expression.
Chen B; Liang T; Yang P; Wang H; Liu Y; Yang F; You G
Oncotarget; 2016 Nov; 7(45):74031-74042. PubMed ID: 27677590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
